Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases

Cancer

Volumn 106, Issue 6, 2006, Pages 1382-1388

  Duan, Xiaoping ^a   Jia, Shu Fang ^a   Koshkina, Nadezhda ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Fas; FasL; Ifosfamide; IL 12; Lung metastasis; Osteosarcoma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIGEN; CYCLINE; FAS LIGAND; IFOSFAMIDE; INTERLEUKIN 12; POLYETHYLENEIMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; GENE THERAPY; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, CD31; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FAS LIGAND PROTEIN; FIBROBLAST GROWTH FACTOR 2; GENE THERAPY; HUMANS; IFOSFAMIDE; INTERLEUKIN-12; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; OSTEOSARCOMA; POLYETHYLENEIMINE; PROLIFERATING CELL NUCLEAR ANTIGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTORS;

EID: 33644838080     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21744     Document Type: Article

References (23)

1. Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99:403-413.
2. Eichhorst ST, Muller M, Li-Weber M, Schuylze-Bergkamen H, Angel P, Krammer PH. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol. 2000;20:7826-7837.
3. Iick RD, Swendeman SL, Coffey DC, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 1999; 59:4392-4399.
4. Roth W, Weller M. Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci. 1999;56:481-506.
5. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst. 1997;89:783-789.
6. Backus HH, Dukers DF, Van Groeningen CJ, Vos W, Bloemena E, Wouters D. 5-Fluorouracil induced Fas up-regulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol. 2001;12:209-216.
7. Mitsiades N, Yu WH, Poulaki VV, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001;61:577-581.
8. Fulda S, Los M, Friesen C, Debatin KM. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer. 1998;76:105-114.
9. Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediated via Fas signaling. Proc Natl Acad Sci U S A. 1997;94:8144-8149.
10. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia. 1999;13:1854-1858.
11. Worth LL, Lafleur EA, Jia S-F, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep. 2002;9:823-827.
12. Lafleur EA, Koshkina NV, Stewart J, et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res. 2004;10:8114-8119.
13. Lafleur EA, Jia S-F, Worth LL, Zhou Z, Owen-Schuab LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res. 2001;61:4066-4071.
14. Jia S-F, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases after intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 2002;9:260-266.
15. Jia S-F, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI:IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res. 2003;9:3462-3468.
16. Duan X, Zhou Z, Jia S-F, Colvin M, Lafleur EA, Kleinerman ES. Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroxperoxycyclophosphamide (4-HC) by a mechanism involving the Fas/Fas-ligand pathway. Clin Cancer Res. 2004;10:777-783.
17. Jia S-F, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis. 1999;17:501-506.
18. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM. Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation- induced apoptosis of brain tumor cells. Cell Death Differ. 1998;5:884-893.
19. Yazawa Y, Takagi T, Asakura S, Suzuki K, Kano Y. Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. J Orthop Sci. 1999;4:231-237.
20. Brade WP, Herdrich K, Varini M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985;12:1-47.
21. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
22. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-49.
23. Fulda S, Susin KA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 1998;58:4453-4460.